Is there a future for FabI inhibitors as antibacterial agents?

ISSN： 2041-6792

Source： Clinical Investigation, Vol.3, Iss.8, 2013-08, pp. : 707-709

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Crystal Structures of Pseudomonas aeruginosa Enoyl‐ACP Reductase (FabI) in the Presence and Absence of NAD+ and Triclosan

BULLETIN OF THE KOREAN CHEMICAL SOCIETY (ELECTRONIC), Vol. 36, Iss. 1, 2015-01 ,pp. : 322-326

John Wiley & Sons Inc

Access to resources Recommend Favorite

7-Piperazinylquinolones with methylene-bridged nitrofuran scaffold as new antibacterial agents

By Emami Saeed Shahrokhirad Nima Foroumadi Alireza Faramarzi Mohammad Samadi Nasrin Soltani-Ghofrani Narges

Medicinal Chemistry Research, Vol. 22, Iss. 12, 2013-12 ,pp. : 5940-5947

Springer Publishing Company

Access to resources Recommend Favorite

Antibacterial Drug Development: Challenges, Recent Developments, and Future Considerations

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 96, Iss. 2, 2014-08 ,pp. : 147-149

John Wiley & Sons Inc

Access to resources Recommend Favorite

The Future of Targeted Therapy: Combining Novel Agents

Oncology, Vol. 63, Iss. 1, 2002-11 ,pp. : 47-56

Karger

Access to resources Recommend Favorite

Comparison of Textilinin-1 with Aprotinin as Serine Protease Inhibitors and as Antifibrinolytic Agents

Pathophysiology of Haemostasis and Thrombosis, Vol. 34, Iss. 4-5, 2006-05 ,pp. : 188-193

Karger

Access to resources Recommend Favorite